Tag Archives: NASDAQ:XERS

Analysts Have Conflicting Sentiments on These Healthcare Companies: Xeris Pharmaceuticals (NASDAQ: XERS) and Evolus (NASDAQ: EOLS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Xeris Pharmaceuticals (XERS – Research Report) and Evolus (EOLS – Research Report). Xeris Pharmaceuticals (XERS) In a report released today, Difei Yang from Mizuho Securities

Mizuho Securities Thinks Xeris Pharmaceuticals’ Stock is Going to Recover

In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Xeris Pharmaceuticals (XERS – Research Report), with a price target of $14.00. The company’s shares closed last Wednesday at $1.67, close to its 52-week low

Mizuho Securities Maintains a Buy Rating on Xeris Pharmaceuticals (XERS)

Mizuho Securities analyst Difei Yang maintained a Buy rating on Xeris Pharmaceuticals (XERS – Research Report) today and set a price target of $18.00. The company’s shares closed last Thursday at $1.56, close to its 52-week low of $1.42. According

Xeris Pharmaceuticals (XERS) Receives a Buy from Mizuho Securities

Mizuho Securities analyst Difei Yang maintained a Buy rating on Xeris Pharmaceuticals (XERS – Research Report) today and set a price target of $22.00. The company’s shares closed last Monday at $6.16, close to its 52-week low of $5.30. According

Xeris Pharmaceuticals (XERS) Gets a Buy Rating from Mizuho Securities

Mizuho Securities analyst Difei Yang maintained a Buy rating on Xeris Pharmaceuticals (XERS – Research Report) today and set a price target of $22.00. The company’s shares closed last Monday at $6.19, close to its 52-week low of $5.30. According

Mizuho Securities Sticks to Its Buy Rating for Xeris Pharmaceuticals (XERS)

Mizuho Securities analyst Difei Yang maintained a Buy rating on Xeris Pharmaceuticals (XERS – Research Report) today and set a price target of $22.00. The company’s shares closed last Monday at $8.23, close to its 52-week low of $6.85. According